Logo-ipp
Submitted: 13 Oct 2019
Accepted: 08 Dec 2019
ePublished: 26 Dec 2019
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

Immunopathol Persa. 2020;6(1): e05.
doi: 10.15171/ipp.2020.05
  Abstract View: 581
  PDF Download: 269

Original Article

Safety and efficacy of high-dose versus low-dose aspirin in individuals with ST elevation myocardial infarction undergoing primary percutaneous coronary intervention: A randomized clinical trial

Abdolhossien Emami Sigaroudi 1 ORCID logo, Arsalan Salari 1 ORCID logo, Mohadeseh Poursadeghi 1, Fatemeh Moaddab 2, Seyedeh Fatemeh Mirrazeghi 1, Fardin Mirbolouk 1 *

1 Cardiovascular Diseases Research Center, Department of Cardiology, Heshmat Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran
2 Department of Nursing, Faculty of Nursing and Midwifery, Islamic Azad University, Rasht, Iran
*Correspondence to Fardin Mirbolouk, Email: Mirbolouk@gums.ac.ir, gums.icrc@gmail.com

Abstract

Introduction: Aspirin is the most frequently used antiplatelet therapy after percutaneous coronary intervention (PCI). Yet, the optimal daily dose of aspirin is unanswered.

Objectives: We aimed to compare the effect of high-dose versus low-dose aspirin in a randomized trial of patients with ST-segment elevation myocardial infarction (STEMI) undergoing PCI.

Patients and Methods: In a double-blind randomized trial, 175 patients with STEMI were randomly assigned to high-dose or low-dose aspirin. The primary efficacy outcome was major adverse cardiovascular events (MACE) as a composite endpoint of death, myocardial infarction, stroke and revascularization procedures. The primary safety endpoint was major bleeding.

Results: Totally 90 and 85 patients were assigned to high-dose and low-dose aspirin, respectively. The incidence rate of MACE was 13.1 and 10.1 per 100 person year in high-dose and low dose aspirin, respectively. There was no significant difference between high-dose and low-dose aspirin in terms of efficacy (Adjusted hazard ratio: 0.85, 95% CI=0.29-2.45) and safety outcome (Adjusted hazard ratio: 1.65, 95% CI=0.41-6.69).

Conclusion: Efficacy and safety outcomes were not significantly different between high-dose and low-dose aspirin.

Keywords: Aspirin, Patients, Percutaneous Coronary Intervention, ST elevation, myocardial Infarction
Citation: Emami Sigaroudi A, Salari A, Poursadeghi M, Moaddab F, Mirrazeghi SF, Mirbolouk F. Safety and efficacy of high-dose versus low-dose aspirin in patients with ST elevation myocardial infarction undergoing primary percutaneous coronary intervention: A randomized clinical trial. Immunopathol Persa. 2020;6(1):e05. DOI:10.15171/ ipp.2020.05.
First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 581

Your browser does not support the canvas element.


PDF Download: 269

Your browser does not support the canvas element.